Recombinant human interleukin-11
| Recombinant human interleukin-11 | |
|---|---|
| Term | Recombinant human interleukin-11 |
| Short definition | recombinant human interleukin-11 - (pronounced) (ree-KOM-bih-nunt HYOO-mun inter-ter-LOO-kin. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
recombinant human interleukin-11 - (pronounced) (ree-KOM-bih-nunt HYOO-mun inter-ter-LOO-kin. . . ) A drug used to increase the number of blood cells, particularly platelets, in some cancer patients who are receiving chemotherapy. Recombinant human interleukin-11 is a laboratory-made form of interleukin-11 (a cytokine normally produced by supporting cells in the bone marrow). It's a kind of biological response modifier. Also called Neumega, Oprelvekin and rhIL-11
External links
- Medical encyclopedia article on Recombinant human interleukin-11
- Wikipedia's article - Recombinant human interleukin-11
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski